Dextran Sulfate Sodium Salt (MW 35000-45000): Model and Mechanism

Executive Summary: Dextran sulfate sodium salt (DSS, MW 35000-45000) is a sulfated polysaccharide widely used to induce experimental colitis in murine models, enabling highly reproducible studies of intestinal barrier disruption and mucosal repair (APExBIO product page). DSS exposure triggers rapid colonic epithelial apoptosis and loss of barrier function, closely mirroring acute and chronic phases of human ulcerative colitis (see Deep Mechanistic Insights). Recent mechanistic advances reveal that epithelial cells sense DSS-induced injury via the GPR35-KLF5 axis, linking mucosal damage to repair programming (Cell Death & Disease 2026). DSS is highly soluble in water and can also inhibit viral entry by blocking adsorption, without affecting coagulation pathways (see Mechanistic Article). APExBIO provides rigorously characterized DSS (B8205), supporting both IBD and virology research.

Biological Rationale

Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon, characterized by recurrent mucosal barrier breakdown and defective epithelial repair. The World Health Organization recognizes UC as a modern, difficult-to-treat disease, with damage to the intestinal mucosal barrier considered the key initiating event (Cell Death & Disease 2026). Rapid and coordinated proliferation and migration of intestinal epithelial cells (IECs) is essential for restoring barrier integrity following injury. The DSS-induced murine model closely recapitulates the epithelial disruption, immune infiltration, and tissue remodeling observed in human disease (see Model Setup). DSS exposure thus serves as a gold-standard for studying mucosal pathogenesis and repair mechanisms in vivo.

Mechanism of Action of Dextran sulfate sodium salt (MW 35000-45000)

DSS is composed of sulfated glucan chains, conferring high polyanionic charge density. When administered orally at 2.5–5% (w/w) in drinking water, DSS selectively targets the colonic epithelium. It disrupts epithelial tight junctions and induces apoptosis, resulting in increased permeability and mucosal ulceration. Cellular and molecular studies reveal that DSS exposure is sensed by IECs via metabolic surveillance pathways, particularly the GPR35 receptor, which monitors changes in tryptophan metabolite flux. Upon detecting damage, GPR35 activates a regulatory circuit involving Kruppel-like factor 5 (KLF5) and the PI3K-AKT-mTOR axis, orchestrating epithelial proliferation and migration for tissue repair (Cell Death & Disease 2026). This mechanistic framework explains both the acute injury and the regenerative processes characteristic of the DSS model.

Evidence & Benchmarks

• DSS at 2.5–5% (w/w) in water induces reproducible colonic inflammation and mucosal damage in mice within 5–7 days (APExBIO product page).
• Histopathology reveals epithelial apoptosis, crypt loss, immune cell infiltration, and ulceration following DSS exposure (Deep Mechanistic Insights).
• The GPR35-KLF5 signaling circuit, activated in response to DSS-induced damage, governs epithelial repair and restoration of barrier function (Cell Death & Disease 2026).
• DSS is soluble in water at concentrations ≥55.5 mg/mL, but insoluble in ethanol and DMSO (APExBIO product page).
• DSS inhibits viral adsorption and entry, such as HIV-1, without significant impact on coagulation (Mechanistic Article).

Applications, Limits & Misconceptions

Applications: DSS (MW 35000-45000) is the reference compound for chemical induction of experimental colitis in mice, allowing quantitative assessment of intestinal barrier disruption, mucosal damage, and regenerative responses. It supports preclinical evaluation of anti-inflammatory and mucosal healing therapeutics, mechanistic studies of epithelial biology, and host-pathogen interaction research. DSS also serves as a polyanionic inhibitor in virology studies, particularly for HIV-1 entry blockade (see Benchmark Article).

Limits: The DSS model primarily reflects epithelial injury and acute inflammation, but does not fully recapitulate chronic fibrosis or transmural disease as seen in Crohn's disease. DSS susceptibility varies by mouse strain and microbiota composition. Solutions are unstable for long-term storage; fresh preparation is recommended. DSS is not a direct therapeutic agent for human IBD.

Common Pitfalls or Misconceptions

• DSS-induced colitis is not equivalent to all forms of IBD; it models acute epithelial injury, not chronic transmural inflammation.
• Results can vary significantly depending on mouse genetic background and gut microbiota; standardization is critical (see Protocol Setup).
• DSS must be dissolved in water; it is insoluble in organic solvents like ethanol or DMSO (APExBIO product page).
• Long-term storage of DSS solutions leads to degradation; use freshly prepared solutions for each experiment.
• DSS is not a direct antiviral drug, but can support mechanistic studies of viral entry inhibition.

Workflow Integration & Parameters

Protocol Parameters

• DSS administration: 2.5–5% (w/w) in drinking water or feed, typically for 5–7 days to induce acute colitis (APExBIO product page).
• Strain selection: C57BL/6 mice are most commonly used; susceptibility varies by strain and microbiota (Model Setup).
• Endpoint assessment: Monitor weight loss, stool consistency, bleeding, and histological scores at 5–10 days.
• Solution preparation: Dissolve DSS powder directly in room temperature water; filter-sterilize if required. Avoid prolonged storage of solutions.
• Control groups: Include water-only controls to distinguish DSS-specific effects from baseline variation.

Conclusion & Outlook

Dextran sulfate sodium salt (MW 35000-45000) remains the gold-standard chemical inducer for acute colitis and epithelial barrier studies in mice. The elucidation of the GPR35-KLF5 circuit provides a high-resolution mechanistic framework for understanding epithelial sensing and repair following DSS injury. These insights inform both preclinical therapeutic development and the design of more predictive intestinal inflammation models. APExBIO's B8205 DSS supports rigorous, reproducible research in IBD and virology. For further methodological detail and protocol troubleshooting, see Precision IBD Mouse Model Setup (this article expands upon their protocol by integrating the latest molecular repair findings), and for in-depth mechanistic exploration, consult Deep Mechanistic Insights (the present article adds new evidence on GPR35-KLF5 linkage). As repair circuitry is further mapped, DSS-based models will continue to inform targeted intervention strategies in ulcerative colitis.